Cynthia Smith
Direktor/Vorstandsmitglied bei AKEBIA THERAPEUTICS, INC.
Vermögen: 181 114 $ am 30.04.2024
Profil
Cynthia Smith is an Independent Director at Agios Pharmaceuticals, Inc., Akebia Therapeutics, Inc., Spero Therapeutics, Inc., and Protara Therapeutics, Inc. She is also a Director at French-American Foundation.
In the past, she worked as an Executive Director-Healthcare System at Merck & Co., Inc., Chief Commercial Officer at ZS Pharma, Inc., and VP-Market Access & Commercial Development at Affymax, Inc. She also served as an Independent Director at Dicerna Pharmaceuticals, Inc. and Nivalis Therapeutics, Inc. Ms. Smith has an undergraduate degree from The University of North Carolina at Chapel Hill, an MBA from The Wharton School of the University of Pennsylvania, and a graduate degree from Eagleton Institute of Politics.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2024 | 65 233 ( 0,03% ) | 86 760 $ | 30.04.2024 | |
| 31.03.2024 | 2 302 ( 0,00% ) | 72 904 $ | 30.04.2024 | |
SPERO THERAPEUTICS, INC.
0,03% | 01.04.2024 | 15 000 ( 0,03% ) | 21 450 $ | 30.04.2024 |
| 11.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Cynthia Smith
| Unternehmen | Position | Beginn |
|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 28.08.2018 |
| SPERO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 19.03.2019 |
| PROTARA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.01.2021 |
| AGIOS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 11.08.2022 |
| French-American Foundation | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Cynthia Smith
| Unternehmen | Position | Ende |
|---|---|---|
| DICERNA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 28.12.2021 |
Nivalis Therapeutics, Inc.
 Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Direktor/Vorstandsmitglied | 01.07.2017 |
| ZS PHARMA INC | Corporate Officer/Principal | 01.12.2016 |
| AFFYMAX, INC. | Corporate Officer/Principal | 01.03.2013 |
| ░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Cynthia Smith
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Eagleton Institute of Politics | Graduate Degree |
| The University of North Carolina at Chapel Hill | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| AFFYMAX, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| SPERO THERAPEUTICS, INC. | Health Technology |
| PROTARA THERAPEUTICS, INC. | Health Technology |
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
ZS Pharma, Inc.
 ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Health Technology |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
| French-American Foundation |
